Cambridge Epigenetix

About:

Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.

Website: http://www.cambridge-epigenetix.com

Twitter/X: cegx_news

Top Investors: Temasek Holdings, Sequoia Capital, Google Ventures, University of Cambridge, Ahren Innovation Capital

Description:

Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.

Total Funding Amount:

$155M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2012-01-01

Contact Email:

info(AT)cegx.co.uk

Founders:

Bobby Yerramilli-Rao, Shankar Balasubramian

Number of Employees:

11-50

Last Funding Date:

2021-11-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai